Literature DB >> 10386679

Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis.

R W Smith1, P A Scott, R J Grant, C R Chudnofsky, S M Frederiksen.   

Abstract

UNLABELLED: Stroke teams are advocated for the rapid treatment of patients who have acute ischemic stroke (AIS) with recombinant tissue plasminogen activator (rt-PA). An alternate model uses existing ED resources with specialist consultation as needed.
OBJECTIVES: To evaluate the treatment of AIS with rt-PA in this alternate ED model.
METHODS: A retrospective observational review was performed of consecutive patients with AIS treated with rt-PA at four hospitals affiliated with an emergency medicine residency. Emergency physicians (EPs) were directly responsible for the treatment of all patients according to predefined guidelines. Records were evaluated from the implementation of the guidelines through December 15, 1997.
RESULTS: 37 patients with AIS received rt-PA. Mean age+/-SD was 63+/-16 years (range 22-87), with 25 (68%) male. Patients presented 67+/-29 minutes after stroke onset. After ED arrival, they were seen by the EP in 14+/-13 minutes, had CT in 46+/-22 minutes, and were treated in 97+/-35 minutes. Neurologist consultation occurred in the department for nine patients (24.3%), and by telephone for 14 (37.8%). Symptomatic intracerebral hemorrhage (ICH) occurred in four (10.8%, 95% CI = 0.8% to 20.8%). There were two deaths, neither associated with ICH. Neurologic outcome at discharge compared with presentation in survivors was normal for four patients (11.4%), improved for 16 (45.7%), unchanged for ten (28.6%), and worse for five (14.3%).
CONCLUSIONS: In this analysis, EPs, with specialty consultation as required, successfully identified patients with AIS and delivered rt-PA with satisfactory outcomes. Important elements of this model include early patient identification, preestablished protocols, and rapid access to CT scanning and interpretation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10386679     DOI: 10.1111/j.1553-2712.1999.tb00416.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  11 in total

1.  Cost-effectiveness of CT perfusion for selecting patients for intravenous thrombolysis: a US hospital perspective.

Authors:  D Jackson; S R Earnshaw; R Farkouh; L Schwamm
Journal:  AJNR Am J Neuroradiol       Date:  2010-06-10       Impact factor: 3.825

2.  Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.

Authors:  Phillip A Scott; Shirley M Frederiksen; John D Kalbfleisch; Zhenzhen Xu; William J Meurer; Angela F Caveney; Annette Sandretto; Ann B Holden; Mary N Haan; Ellen G Hoeffner; Sameer A Ansari; David P Lambert; Michael Jaggi; William G Barsan; Robert Silbergleit
Journal:  Acad Emerg Med       Date:  2010-10       Impact factor: 3.451

3.  Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study.

Authors:  Michael D Hill; Alastair M Buchan
Journal:  CMAJ       Date:  2005-05-10       Impact factor: 8.262

4.  Comparison of neurological clinical manifestation in patients with hemorrhagic and ischemic stroke.

Authors:  Seyedhossein Ojaghihaghighi; Samad Shams Vahdati; Akram Mikaeilpour; Ali Ramouz
Journal:  World J Emerg Med       Date:  2017

5.  Resident-based acute stroke protocol is expeditious and safe.

Authors:  Andria L Ford; Lisa Tabor Connor; David K Tan; Jennifer A Williams; Jin-Moo Lee; Abdullah M Nassief
Journal:  Stroke       Date:  2009-01-29       Impact factor: 7.914

Review 6.  Enhancing community delivery of tissue plasminogen activator in stroke through community-academic collaborative clinical knowledge translation.

Authors:  Phillip A Scott
Journal:  Emerg Med Clin North Am       Date:  2009-02       Impact factor: 2.264

7.  Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community Hospitals.

Authors:  Eric E Adelman; Phillip A Scott; Lesli E Skolarus; Allison K Fox; Shirley M Frederiksen; William J Meurer
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-09-26       Impact factor: 2.136

8.  Early and intermediate prognosis of intravenous thrombolytic therapy in acute ischemic stroke subtypes according to the causative classification of stroke system.

Authors:  Ali Pashapour; Abolfazl Atalu; Mehdi Farhoudi; Ali-Akbar Taheraghdam; Elyar Sadeghi Hokmabadi; Ehsan Sharifipour; Mehdi Najafineshli
Journal:  Pak J Med Sci       Date:  2013-01       Impact factor: 1.088

9.  Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: feasibility and effectivity from an Indian perspective.

Authors:  S R Sharma; Nalini Sharma
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

10.  Determining intravenous rt-PA eligibility in the Emergency Department.

Authors:  Amy C Mecozzi; Devin L Brown; Lynda D Lisabeth; William G Barsan; Robert Silbergleit; Susan L Hickenbottom; Phillip A Scott; Lewis B Morgenstern
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.